Florian Burtin
Overview
Explore the profile of Florian Burtin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
171
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burtin F, Elias L, Hinz S, Forster M, Hildebrandt G, Frerker B, et al.
J Cancer Res Clin Oncol
. 2024 Sep;
150(9):428.
PMID: 39307893
Background: Liquid biopsy is a minimally invasive procedure investigating tumor mutations. Methods: In our retrospective study, we investigated whether molecular therapy monitoring of patients receiving neoadjuvant radio(chemo)therapy on a daily...
2.
Burtin F, Ludwig T, Leuchter M, Hendricks A, Schafmayer C, Philipp M
J Clin Med
. 2024 Jan;
13(1).
PMID: 38202180
Background: The Physiological and Operative Severity Score for the enUmeration of Mortality and Morbidity (POSSUM) weights the patient's individual health status and the extent of the surgical procedure to estimate...
3.
Fan Y, Fong Y, Kuo C, Li C, Chen W, Lin J, et al.
Cell Biosci
. 2023 Aug;
13(1):147.
PMID: 37563620
Background: Pancreatic ductal adenocarcinoma (PDA) is a pernicious disease characterized by an immunosuppressive milieu that is unresponsive to current immunotherapies. Interleukin-1 receptor antagonist (IL-1Ra) is a natural anti-inflammatory cytokine; however,...
4.
von den Driesch J, Flottmann J, Prall F, Mullins C, Linnebacher M, Burtin F
Front Oncol
. 2023 Feb;
12:1082927.
PMID: 36761421
Introduction: Medullary pancreatic carcinoma (MPC) is a rare subtype of pancreatic ductal adenocarcinoma. MPCs represent less than 1% of all pancreatic cancers, and, with only 26 cases in the literature,...
5.
Kdimati S, Burtin F, Linnebacher M, Mullins C
Methods Mol Biol
. 2022 Oct;
2589:111-126.
PMID: 36255621
Patient-derived organoids are promising tumor models for functional validation of next-generation sequencing-based therapy recommendations. In times of rapidly advancing precision oncology approaches in everyday clinical processes, reliable and valid tumor...
6.
Pfohl U, Loskutov J, Bashir S, Kuhn R, Herter P, Templin M, et al.
Cancers (Basel)
. 2022 Jul;
14(13).
PMID: 35805024
In colorectal cancer (CRC), mutations of genes associated with the TGF-β/BMP signaling pathway, particularly affecting , are known to correlate with decreased overall survival and it is assumed that this...
7.
Matschos S, Burtin F, Kdimati S, Radefeldt M, Krake S, Prall F, et al.
Cancers (Basel)
. 2021 Dec;
13(23).
PMID: 34884989
Based on our research group's large biobank of colorectal cancers (CRC), we here describe the ongoing activity of establishing a high quality assured PDX biobank for more than 100 individual...
8.
Wagner S, Beger N, Matschos S, Szymanski A, Przybylla R, Burtin F, et al.
Cancers (Basel)
. 2021 Sep;
13(18).
PMID: 34572946
The prognosis of metastatic colorectal cancer (CRC) remains poor. Patients and physicians are in need of individual therapies and precise response predictions. We investigated the predictive capacity of primary tumour...
9.
Burtin F, Matschos S, Prall F, Mullins C, Krohn M, Linnebacher M
J Vis Exp
. 2021 Apr;
(170).
PMID: 33900297
In light of the growing knowledge about the inter-individual properties and heterogeneity of cancers, the emerging field of personalized medicine requires a platform for preclinical research. Over recent years, we...
10.
Burtin F, Mullins C, Linnebacher M
World J Gastroenterol
. 2020 Apr;
26(13):1394-1426.
PMID: 32308343
Colorectal cancer (CRC) is the third most common diagnosed malignancy among both sexes in the United States as well as in the European Union. While the incidence and mortality rates...